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The proto oncogene tyrosine kinase ROS1, which is located at 
6p22 on chromosome 6, plays a key role in carcinogenesis 
through gene rearrangements. Gene rearrangements result in the 
expression of fusion proteins from partner genes. ROS1 fusion 
proteins consist of the C-terminal intracellular region of ROS1 
and the N-terminal extracellular region of other partners. 
However, the full-length wild type ROS1 has rarely been 
reported. The possibility of full-length ROS1 expression has 
been proposed to be under epigenetic regulation. Here, the 3B20 
scFv antibody, which is reactive to the N-terminal region of 
ROS1, was generated for the detection of full-length ROS1 in 
cancerous tissues. Unfortunately, in testing the reactivity of the 
3B20 scFv antibody, cross-reactivity to the heat shock protein 
(Hsp) 70 family was also observed during immunoblot and 
immunoprecipitation analyses. Sequence homology indicated that 
the Asp, Leu, Gly, and Thr (DLGT) amino acid sequence was 
shared between ROS1 and Hsp70s. In addition, the epitope was 
confirmed to harbor this amino acid sequence by alanine scanning 
mutagenesis of ROS1. To modify the idiotope, which is the unique 
antigenic determinant of an antibody, random mutations were 
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introduced into the heavy chain complementary determining 
region 3 (HCDR3) of the 3B20 scFv antibody. Consequently, a 
site-direct mutagenesis HCDR3 library was constructed 
specifically to eradicate cross-reactivity of the 3B20 scFv 
antibody while maintaining its binding affinity to ROS1. Finally, a 
new anti-ROS1 clone, 3B20-H1-13 scFv, was successfully 
generated through point mutation. The 3B20-H1-13 scFv 
antibody was shown to only react with ROS1 in enzyme-linked 
immunosorbent assay (ELISA), immunoblot, and immune-
precipitation analyses. Immunohistochemistry (IHC) using 
3B20-H1-13 scFv showed that ROS1 was absent in non-
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1. Lung cancer and its tumor specific factors 
Lung cancer is one of the leading causes of cancer-related death 
worldwide. The primary cause of lung cancer is smoking. 
However, more than 60% of new cases of lung cancer comprise 
non-smokers, and 20% women and 8% men diagnosed with lung 
cancer are non-smokers [1]. Lung cancer is divided into three 
types, non-small cell lung cancer (NSCLC), small cell lung 
cancer, and large cell lung carcinoma. NSCLC is the most 
common type and accounts for 85–90% of lung cancers [2]. 
Additionally, the survival rate of patients after the diagnosis of 
NSCLC in stage IV is extremely low (less than 5%). NSCLC can 
also be divided into three main subtypes. The histological 
subtypes of NSCLC are adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma. In the US, 40% of lung 
cancer patients suffer from adenocarcinoma [3]. Adeno-
carcinoma in NSCLC is known to have several of tumor specific 
factors, such as KRAS, EGFR, ALK, RET, BRAF, etc [4]. These 
tumor specific factors have been focused in several studies and 
cancer therapies. However, these factors must be investigate 
accurately. For example, copy number variation of EGFR in 
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Asians has been reported to be more frequent than that of KRAS 
in non-Asians [5]. Furthermore, in the case of mutated EGFR, 
gefitinib, which is an EGFR inhibitor, has been used in the 
treatment of NSCLC patients [6]. Such studies also indicate the 
importance of investigating tumor specific factors in lung cancer. 
 
2. ROS1 in Lung cancer 
Currently, various tumor specific factors expressed in lung 
cancer have been consistently studying, and one of them is 
proto-oncogene tyrosine kinase ROS1 (ROS1). ROS1 is the 
orphan receptor tyrosine kinases (RTKs), and has a large 
extracellular domain that is composed of fibronectin repeats, a 
transmembrane domain, and an intracellular kinase domain 
(Table 1). It was first reported in 1986 [7], and was isolated 
from human glioblastoma cells. ROS1 gene rearrangements was 
first verified in glioblastoma cell lines [8, 9]. It has been shown 
that the ROS1 gene on chromosome 6q22 can be rearranged with 
various partners (Figure 1). Therefore, truncated ROS1 protein 
can be expressed in multiple fusion proteins, where the 3′ region 
of ROS1 is fused to the 5′ region of v-ros [10], FIG [11], 
SLC34A2 [12, 13], CD74 [13], EZR [14], LRIG39 [14], TPM3 
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[14], and SDC4 [15]. In recent studies, ROS1 rearrangements 
have also been observed in non-small cell lung cancer (NSCLC) 
[12, 15, 16] and human cholangiocarcinoma [17]. The frequency 
of ROS1 rearrangement in NSCLC is known to approximately1-
2% [12]. Additionally, it is reported that the presence of ROS1 
gene copy number gain (CNG) was significantly associated with 
a higher risk of recurrence of lung cancer, and shorter survival 
than without ROS1 gene CNG [18]. Furthermore, ROS1 gene 
CNG is seen as sign an independent poor prognostic factor in 
NSCLC patients with surgical resection. Therefore, detection of 
ROS1 is very meaningful to lung cancer patients. ROS1 is known 
to activate cell signaling associated with proliferation, metastasis, 
and anti-apoptosis [19];however, its biological functions remain 
unclear. A lack of adequate information such as unidentified 
ligand and/ or absence of ROS1 cell lines expressing full-length 
wild type protein lead to limitations in ROS1 research. Therefore, 
it is necessary to develop proper antibodies that specifically bind 
to full-length ROS1, but not to the fusion forms. 
 
3. Overview of antibody phage display technology 
When screening an antibody for target molecules, a single chain 
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fragment variable (scFv) or fragment antigen binding (Fab) are 
mainly used. Because those molecules size are small than IgG, 
and it will be simple to handle. After that, a scFv or Fab could be 
displayed on surfaces of phages, yeasts, bacteria, and ribosomes. 
Phage display using bacteriophage is a well-known display 
method; the pIII minor and pVIII major capsid proteins on the 
phage surface display antibodies, small proteins, or peptides. 
Phage display technology was first introduced in 1985 by George 
P. Smith [20], where foreign DNA fragments were inserted into 
the filamentous phage genome. The phage particle is known to 
approximately 930 nm in size [21]. The majority of the 
bacteriophage surface is covered with the 50 amino acid major 
capsid protein pVIII, at approximately 2,700 copies per phage. 
The end of the phage particles is composed of minor coat 
proteins, pIII, pVI, pVII and pIX. All five capsid proteins on the 
phage particle can be used for phage display. Especially, the pIII 
and pVIII domains have been frequently used to display peptides 
and proteins in phage display libraries, as the amino terminal 
portion of pVIII is present on the outside of phage particles. 
However, pVIII type phage display libraries have a peptide 
insertion limit of 6-8 amino acids in length. On the other hand, 
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the pIII capsid protein consists of three domains, which are N1 
or D1, N2 or D2, and CT or D3 domains. The N1 and N2 domains 
are exposed on the surface of phage particles. Using the pIII 
phage particle, only approximately 1-2 molecules can be 
displayed per phage particle. However, it is possible that large 
insert molecules are well packaged into phage particles, such as 
scFv, Fab, or other large proteins. Hence, phage display can be 
used in antibody fragment screening, where it binds to target 
molecules. Another advantage in using bacteriophage is that it is 
an economical, high-throughput method, which may arise from 
its own peculiarities, such as high phage infectivity to E.coli cells; 
infected E.coli cells can produce more than a thousand identical 
phages. In addition, bacteriophages remain stable under various 
physicochemical stresses, including freeze and thaw cycles [22], 
as well as exposure to low [23] or high pH [24]. Therefore, 
bacteriophages can be utilized in various experiments, especially 
in the phage display system. Similarly, to develop antibody that 
specifically bind to full-length ROS1, chicken scFvs displayed 





4. Using bio-panning as antibody screening platform 
Bio-panning is an affinity selection method for screening 
antibodies from phage display libraries. The typical process for 
bio-panning is as follows (Figure 2). First, antibody fragments 
(scFv or Fab) are displayed on the surface of bacteriophages 
through antibody fragments-displayed phage library. This 
library contains a large proportion of antibody displayed on phage. 
The antibody fragments-displayed phage library is then mixed 
with target molecules, such as peptides and proteins. At this time, 
target molecules must be immobilized on solid supports, such as 
magnetic beads [25], column matrix [26], nitrocellulose [27], 
polystyrene tubes [28], and 96 well micro-titer polystyrene 
plates [29]. Non-binding phages are washed out using 
detergents during the washing steps. Next, the phage bound 
target molecules are amplified by infecting E.coli cells, and this 
process is repeated. Specific selection processes are then 
carried out to isolate antibodies against target molecules. Above 
mentioned bio-panning was used as a well-established 
screening method to detect the anti-ROS1 scFv antibody. This 
screening method during natural interactions between antibodies 
and target molecules is the greatest advantage of phage display 
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technology. That is also applicable to interaction between scFvs 
and ROS1 protein, and it is possible to select scFv that 
specifically binds to ROS1 protein. Consequently, antibodies 
selected this process will be a valuable tool.  
 
5. Applicability of mass spectrometry analysis to an antibody 
Mass spectrometry (MS) analysis is an analytical method that is 
frequently used to detect intact proteins, peptides, post-
translation modifications (PTMs), and metabolites [30]. 
Moreover, MS analysis could be employed to characterize 
monoclonal antibody (mAb), including glycosylation, deamidation 
[31], structure [32], and molecular weight of intact mAbs. Thus, 
optimized MS analysis has become an essential analytical tool for 
characterization of mAbs. For example, FDA-approved 
therapeutic mAbs such as trastuzumab [33], and rituximab [34], 
were both analyzed and characterized using MS analysis. 
Furthermore, MS analysis also can be performed with specific 
antibodies to identify specific protein interaction partners; the 
protein of interest, along with its partner, is isolated with a 
specific antibody and then analyzed by MS [35]. Antibody-
protein interactions followed by subsequent MS analysis are very 
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useful for investigation of unknown proteins. For example, 
dopamine transporter (DAT) interaction proteins, 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) β, and 
CaMKII δ were identified from rat striatal synaptosomes by 
anti-DAT antibodies and LC-MS/MS [36]. Co-immuno-
precipitation coupled with MS analysis can identify unknown or 
multiple protein binding partners. More particularly, liquid 
chromatography coupled with tandem mass spectrometry (LC-
MS/MS) data is generally quantified using the spectral counting 
[37]. Spectral counting is based on the observation of identified 
number of spectra, and more abundant peptides will be selected 
for fragmentation [38]. And then, protein can be predicted from 
the collected abundant peptides. The anti-ROS1 scFv antibody 
developed through bio-panning was observed non-specific 
binding to some protein, not ROS1. Above mentioned method was 
actually used to identify non-specific binders of anti-ROS1 scFv 
antibody. The protein was identified using spectral counting, and 
the information of that was very helpful in the characterization 
and modification of the developed antibody.  
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6. Specificity of an antibody 
Antibodies development by several methods, including bio-
panning are widely used for antigen detection in various assays, 
such as enzyme immunoassays, radioimmunoassays, and 
fluorescence immunoassays. For these assays, antibodies can be 
labeled with diverse compounds including enzymes, 
radioisotopes, and fluorochromes. Also, various antibody 
technologies for simultaneous detection of multiple antigens are 
under active development. In brief, numerous mAb are being 
developed each year for specific assays; however, many of these 
mAbs have demonstrated cross-reactivity, variability in quality, 
and have been used in wrong applications [39]. The Human Atlas 
is an open database that stores protein profiles based on 
thousands of antibodies against cancer, normal tissues, and cell 
lines. This database is heavily antibody dependent; however, it 
has been reported that more than 50% of commercially available 
antibodies have poor specificity, or do not work at all [40]. 
Furthermore, most commercially available antibodies 
demonstrate cross-reactivity. During the establishment of the 
size exclusion chromatography-microsphere based affinity 
proteomics (SEC-MAP) method, more than 1,500 commercially 
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available antibodies were tested by size exclusion 
chromatography (SEC). Results indicated that most 
commercially available antibodies bind to more than one target 
[41]. That is very undesirable, because antibody are considered 
an reaction of one antigen. Eventually, it is related to antibody’s 
specificity. Antibody specificity refers to the ability of antibody 
which reacts with a one target. The key advantage of using mAbs 
in therapy, agonist, antagonist, and ELISA kit is also its 
specificity. Occasionally, antibody specificity is regarded as a 
magic bullet. That is why antibody specificity should be 





PURPOSE OF THE STUDY 
The proto oncogene tyrosine kinase ROS1 is an orphan receptor 
whose ligand has not yet been identified. Due to the unidentified 
ligand, the functions of wild type ROS1 are almost unknown. The 
ROS1 gene is unique in that it frequently undergoes gene 
rearrangements. Therefore, the ROS1 protein is mainly 
expressed in fusion proteins with N-terminal partners including 
FIG, CD74, and SLC34A2. The function of ROS1 has been studied 
from these fusion ROS1 proteins. To investigate the expression 
of wild type ROS1, an antibody that binds to the N-terminal of 
ROS1 is required. Furthermore, N-terminal binding of the ROS1 
antibody could enable it to act as an agonist or antagonist. The 
writer of this thesis developed an anti-ROS1 scFv antibody, 
which was able to bind to the N-terminus of ROS1. The anti-
ROS1 scFv antibody epitope was well-defined by alanine 
scanning mutagenesis, and showed high reactivity against ROS1. 
However, cross-reactivity to Hsp70s was observed in anti-
ROS1 scFv antibody as well. To eradicate cross-reactivity, a 
point mutation was introduced into the HCDR3 of the antibody. 
The purpose of this study was to develop an anti-ROS1 scFv 
antibody, and to enhance its specificity through point mutations 
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in the HCDR3. The modified anti-ROS1 scFv antibody can be 
useful in investigating the full-length ROS1, and can reveal 




MATERIALS AND METHODS 
1. Development of anti-ROS1 scFv antibody, 3B20 
1-1. Immunization of ROS1 peptide  
Three White Leghorn chickens were immunized four times with 
the synthetic peptide (TNLGQQLDLGTPHNLSEPGGGC) of 
ROS1 (NCBI Reference Sequence: NP_002935.2) conjugated 
with keyhole limpet hemocyanin (KLH) (Peptron; Daejun, 
Korea). Boost immunizations were performed at three times in 
chickens with 2-3 week intervals. (Table 2) The antibody titer 
was determined by enzyme linked immunosorbent assay (ELISA) 
against ROS1 peptide and recombinant proteins. 
 
1-2. Enzyme-linked immunosorbent assay with immunized 
chicken serum 
ELISA using immunized chicken serum was performed against 
ROS1 N-terminus peptide and recombinant ROS1 proteins. 
Ninety-six well microtiter plates (Corning Costar Corp., 
Cambridge, MA, USA) were coated with 100 ng of ROS1 N-
terminus (39~56) peptide conjugated with bovine serum 
albumin (BSA), recombinant ROS1 (37-290 amino acids)-hFc 
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and CK fusion protein per well for overnight at 4℃. After day, the 
wells were blocked with 100 μL of 3% BSA in PBS. Chicken 
sera of first injection, 1st boosting, and 2nd boosting were diluted 
1/500, 1/1000, 1/2000, 1/4000, and 1/8000 in 3% BSA in PBS. 
Each diluted chicken sera added to well and incubated for 2 h at 
37℃. After washing with 0.05% Tween 20 in PBS (PBST) three 
times, plates were incubated with HRP conjugated anti-chicken 
IgY antibody (Merck, Kenilworth, NJ, USA). Washing steps were 
repeated three times. 2,2’-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) (ABTS, Amresco, Solon, OH, USA) in 0.05 M 
Citric acid buffer (pH 4.0) and 1.0% H2O2 were added to each 
well. Optical density was measured at 405 nm with microplate 
photometer (Labsystems Multiskan Ascent microplate reader, 
Thermo Fisher Scientific, Rockford, IL, USA) 
 
1-3. Immunoblot assay with immunized chicken serum 
HEK 293T cells transfected with Lentiviral vector encoding 
human ROS1 and GFP cell lysates were separated on 4-12% 
Bis-Tris SDS-polyacrylamide gel (Thermo Fisher Scientific) 
and transferred to a nitrocellulose membrane (Whatman, 
Maidstone, Kent, UK). The membrane was blocked with 5% skim 
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milk in Tris-buffered saline (TBS) containing 0.2% tween-20 
at room temperature for 1 h and then incubated overnight with 
the 1st boosting, and 2nd boosting sera. The serum was diluted 
1/2000 in blocking buffer. The membrane was washed five times 
with 0.2% tween-20 in TBS. HRP-conjugated anti-chicken IgY 
antibody (Merck) were used as secondary antibodies diluted 
1:5000 in blocking buffer for 1 h at room temperature. The blots 
were visualized using the enhanced chemiluminescence system 
(Thermo Fisher Scientific), according to the manufacturer’s 
instructions. 
 
1-4. Extraction of total RNAs and synthesis of cDNAs 
Total RNAs was isolated from the harvested spleen, bone 
marrow, and bursa of Fabricius using the TRI Reagent® (Thermo 
Fisher Scientific) according to the manufacturer’s instruction. 
First-strand cDNAs were synthesized using the synthesized 
First-strand cDNA kit (Thermo Fisher Scientific) and first round 
of PCR was performed using Expand High Fidelity PCR system 
(Roche, Basel, Switzerland). For chicken scFv libraries, one 
primer combination was used for each of Vλ and VH amplification 
(Table 3, Figure 3).  
16 
 
1-5. Construction of chicken scFv phage display libraries 
Three phage displayed chicken single-chain variable fragments 
(scFv) libraries were constructed using the pComb3XSS 
phagemid vector. In each reaction, one μL of cDNA was mixed 
with 80 pmol of each primer, 10 μL of 10 X reaction buffer, 8 
μL of 2.5 mM dNTPs, 1 μL of Taq DNA polymerase and water 
to a final volume of 100 μL. The PCR reactions were carried out 
under the following condition: 30 cycles of 15 s at 94℃, 30 s at 
56℃, and 90 s at 72℃, followed by a final extension for 10 min 
at 72℃. Amplified fragments with length of approximately 350 
base pairs were loaded and run on a 1.5% agarose gel, and 
purified with Gel Extraction Kit (Qiagen, Netherlands, Hilden, 
Germany). The primer sets for this were as described above. 
(Table 3) In the second round of PCR, the first round VL products 
and VH products were randomly joined by overlap extension PCR. 
Overlap Extension Primers sets were as described above. 
(Table 3) Each PCR reaction was performed in a 100 μL 
mixture composed of 100 ng of purified VL product and VH 
product, 60 pmol of each primer, 10 μL of 10 X reaction buffer, 
8 μL of 2.5 mM dNTPs and 1 μL of Taq DNA polymerase. The 
PCR reactions were carried out under the following condition: 20 
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cycles of 15 s at 94℃, 30 s at 56℃, and 2 min at 72℃, followed 
by a final extension for 10 min at 72℃. About 700 base pairs 
sized scFv fragments were purified with Gel Extraction Kit 
(Qiagen). The scFv fragments and pComb3XSS phagemid 
vectors were digested with Sfi I restriction enzyme (Roche) by 
incubating for 8 h at 50℃. Seven hundred ng of Sfi I-digested 
scFv was ligated with 1,400 ng of pComb3XSS phagemid vector 
using T4 DNA ligase (Thermo Fisher Scientific) by incubating 
the reaction mixture for 16 h at 16℃, followed by ethanol 
precipitation.  
 
1-6. Amplification of phage display libraries 
Ligated library DNA was transformed into 300 μL of 
electrocompetent E. coli ER2738 (New England Biolabs, Beverly, 
MA, USA) by electroporation with a 0.2 cm cuvette and Gene 
Pulser (Bio-Rad Laboratories, Hercules, CA, USA) at a condition 
of 2.5 kV, 25 μF and 200 Ω. The cells were resuspended with 3 
mL of Super Broth (SB) medium and incubated for 1 h at 37℃ 
while shaking at 250 rpm. 10 mL of SB medium and 3 μL of 100 
mg/mL carbenicillin were added to the culture. The library size 
was determined by plating 0.1, 1 and 10 μL of the culture on 
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Luria Broth (LB) plate containing 50 μg/mL of carbenicillin. After 
one hour of incubation, 4.5 μL of 100 mg/mL carbenicillin was 
added to the culture and incubate for an additional hour. The 
culture was added to 10 mL of VCSM13 helper phage (> 1011 
cfu/mL, New England Biolabs), 173 mL of SB medium and 92.5 
μL of 100 mg/mL carbenicillin and incubated for 2 h at 37℃ 
while shaking at 250 rpm.  Kanamycin (280 μL) was added to 
the culture, and the culture was shaken overnight at 250 rpm and 
37℃. The next day, the culture was centrifuged at 3,000 x g for 
15 min. The bacterial pellets were saved for phagemid DNAs 
preparation and the supernatant was transferred to clean 
centrifuge bottle. Eight grams of polyethylene glycol-8000 
(PEG-8000) and 6 g of NaCl (Merck) were added, and the 
supernatant was stored on ice for 30 min. The supernatant was 
spun at 15,000 x g for 15 min at 4℃. The phage pellets were 
resuspended in Tris-buffered saline (TBS) containing 1% BSA.  
 
1-7. Preparation of bacteriophages 
A single plaque was selected from the titration plate and used to 
infect 10 mL of E. coli ER2738 cells in the exponential growth 
phase, optical density at 600 nm (OD600) = 0.8. The cells were 
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allowed to grow with shaking at 250 rpm for 2 h at 37 °C. The 
culture was added to 500 mL of SB containing kanamycin (70 
g/mL) and incubated overnight at 37 °C with shaking at 250 rpm. 
After centrifugation at 3,000 x g for 15 min, the culture was 
transferred to 500 mL tubes and incubated in a water bath at 
70 °C for 20 min. The culture was then centrifuged at 3,000 x g 
for 15 min. Finally, the supernatants transferred to new tubes 
and stored at 4 °C until used.  
 
1-8. Preparation of electro-competent cells 
A single colony of E. coli ER2738 was inoculated to 10 mL of 
prewarmed SB medium and incubated overnight at 37℃. The 
next day, 2.5 mL of the culture was transferred into 500 mL SB 
medium containing 10 mL of 20% (w/v) glucose and 5 mL of 1 M 
MgCl2 and shook at 250 rpm and 37℃ until the OD600 reaches 0.8. 
The culture was poured into prechilled 500 mL of centrifuge 
bottle and incubated 15 min on ice. The culture was separated 
into supernatant and pellets by centrifugation at 3,000 x g for 20 
min at 4℃. The supernatant was discarded and the pellets were 
resuspended in 250 mL of prechilled 10% (w/v) glycerol solution. 
The resuspension was spun as before. After three times of 
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pellets washing, the supernatant was discarded and the pellets 
were resuspended in 3 mL of 10% glycerol solution, and 
aliquoted at small volumes stored at -80℃. 
 
1-9. Bio-panning 
Two point five μg of ROS1 N-terminus (39~56) peptide 
conjugated with KLH and recombinant ROS1 (37-290 amino 
acids)-hFc were coated to 5 x 106 dynabeads (M270- Epoxy, 
Thermo Fisher Scientific) at room temperature for 18 h. The 
beads were washed with 500 μL of 3% BSA in PBS at 5 times 
and blocked with 3% BSA in PBS at room temperature for 1 h. 
After washing of ROS1 peptide and protein coated beads with 0.5% 
PBST briefly, beads were incubated with phage-displayed scFvs 
at room temperature for 2 h. The beads were washed with 500 
μL of 0.5% PBST for removing unbound phage. The number of 
washing steps was increased from once in first round to 5 times 
in fifth round of panning. Bound phages were eluted using 60 μ
L of 0.1 M Glycine-HCl (pH 2.2) at twice and neutralized by 6 
μL of 2 M Tris-HCl (pH 9.1). Eluted phages were used to infect 
2 mL of E. coli ER2738 and the phagemid was rescued with 5 mL 
of VCSM13 helper phage for overnight amplification. The input 
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and output phage titer were determined by plating the phage 
infected bacterial culture on LB plate containing 50 μg/mL of 
carbenicillin. Next day, the phage was precipitated by adding PEG 
and NaCl as described above. 
 
1-10. Individual phage enzyme-linked immunosorbent 
assay  
ELISA using phages displaying scFvs was performed against 
ROS1 peptide and protein to analyze the selected clones from 
bio-panning. Ninety-six well microtiter plates (Corning Costar 
Corp.) were coated with 100 ng of ROS1 N-terminus (39~56) 
peptide conjugated with BSA, recombinant ROS1 (37-290 amino 
acids)-hFc and mouse anti-Hemagglutinin (HA) antibody per 
well for overnight at 4℃. After day, the wells were blocked with 
100 μL of 3% BSA in PBS. Each phage culture was mixed with 
an equal volume of 6% BSA in PBS and incubated for 2 h at 37℃. 
After washing with 0.05% PBST three times, plates were 
incubated with HRP conjugated anti-M13 antibody (GE 
Healthcare Life Sciences, Piscataway, NJ, USA). Washing steps 
were repeated three times. ABTS solution in 0.05 M Citric acid 
buffer (pH 4.0) and 1.0% H2O2 were added to each well. Optical 
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density was measured at 405 nm with microplate photometer 
(Labsystems Multiskan Ascent microplate reader, Thermo 
Fisher Scientific) 
 
2. Overexpression and purification of anti-ROS1 scFv 
antibody 
2-1. Sub-cloning of anti-ROS1 scFv antibody into Fc and 
CK vector 
The vector carries an expression cassette composed of the 
leader sequence of the human Ig κ-chain, two Sfi I sites for 
insertion of the antibody gene of interest, the hinge region of 
human IgG1,and the CH2–CH3 domains of rabbit IgG. For CK fusion, 
gene encoding human IgG1 hinge and human CK was inserted into 
pCEP4 vector. Then the gene encoding anti-ROS1 scFv antibody 
derived bio-panning was sub-cloned in the 5’ end of Fc region 
by two Sfi I restriction sites, followed by ligation using T4 DNA 







2-2. Transient transfection and affinity chromatography 
purification 
DNA for transfection was prepared using PureLink HiPure 
Plasmid Maxi-prep kit (Thermo Fisher Scientific), according to 
the manufacturer’s instructions. Transfection was performed 
into HEK 293F cells (1.0 x 106 cells/mL, Thermo Fisher 
Scientific) using polyethylenimine (PEI, Polysciences, 
Warrington, PA, USA). Two point five μg of mammalian 
expression vector per mL of culture volume and 5 μg of 
polyethyleneimine/mL were mixed in 150 mM NaCl (1/10 volume 
of total), and let stand at room temperature for 15 min. The 
mixture was added to the HEK 293F cells (2 x 10 6 cells/mL, 
Thermo Fisher Scientific) and cultured for 6 days under the 
following condition : FreeStyle™ 293 Expression medium 
(Thermo Fisher Scientific) containing 100 U/mL penicillin 
(Thermo Fisher Scientific) and 100 U/mL streptomycin (Thermo 
Fisher Scientific), 37℃, 7% CO2, 135 rpm on an orbital shaker. 
Each protein was purified by protein A agarose beads (Repligen, 
Waltham, MA, USA) or the KappaSelect resin (GE Healthcare, 




3. Construction and production of lentivirus 
To generate the pLenti6-human ROS1-DEST construct, 
pENTR223.1-human ROS1 (Open Biosystems, Huntsville, AL, 
USA) was transferred into pLenti6/V5-DEST (Thermo Fisher 
Scientific) through Gateway recombination cloning technology 
using Gateway LR ClonaseTM (Thermo Fisher Scientific) 
according to manufacturer’s instructions. The pLenti6-human 
ROS1-DEST construct used for lentiviral production was 
confirmed by sequencing through Primer Walking system 
(Macrogen, Seoul, South Korea). To produce negative control 
virus to be used, green fluorescent protein (GFP) was also 
cloned into the same lentiviral vector. 
Lentivirus was produced by transient transfection of HEK 293T 
cells. pLenti6-GFP-DEST or pLenti6-human ROS1-DEST 
lentiviral construct was co-transfected with vesicular stomatitis 
virus glycoprotein (VSV-G) plasmid DNA and delta 8.9 (Gag-
pol) plasmid DNA for viral packaging into HEK 293T cells using 
lipofectamine 2000 (Thermo Fisher Scientific) reagent according 
to manufacturer’s instructions. The medium was replaced with 
fresh medium at 6 h post-transfection. Supernatant of 
transfected cells were harvested at 48 h after transfection and 
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filtered by 0.45 μm membrane (Pall Corporation, Washington, 
NY, USA). Viral particles were concentrated and purified using a 
Lenti-X concentrator (Clontech Lab, Mountain View, CA, USA) 
according to manufacturer’s instructions. 
 
4. Transduction and establishment of ROS1 stable cell line  
To generate full-length recombinant ROS1 overexpressing cell 
lines, HEK 293T cell were infected with pLenti6-GFP-DEST or 
pLenti6-human ROS1-DEST expressing lentiviruses in the 
presence of 6 μg/mL polybrene. The transduction efficiency 
was determined by parallel control experiments. Green 
fluorescence of the cells transduced with GFP lentivirus 
generated at the same time with ROS1 lentivirus was observed 
after 72 h. Antibiotic selection using 10 μg/mL of blasticidin 
(Thermo Fisher Scientific) was performed on the virally infected 
cells for 7 days. The blasticidin resistant lentivirus infected cells 
were selected and stable cell lines were established. mRNA and 
protein expression level of human ROS1 were verified by 
reverse transcription polymerase chain reaction (RT-PCR) and 




5. Cell culture 
HEK 293T lentiviral transfected ROS1 and GFP cells were 
cultured in Dulbecco's modified Eagle's medium (DMEM; 
Welgene, Seoul, Korea) supplemented with 10% heat inactivated 
FBS (GIBCO, Grand Island, NY, USA), 100 U/mL penicillin and 
100 mg/mL streptomycin, 2 mM L-Glutamine (GIBCO) in a 
humidified 5% CO2 atmosphere at 37℃. 
 
6. Immunoblots 
Cell lysates were separated on 4-12% Bis-Tris SDS-PAGE gel 
(Thermo Fisher Scientific) and transferred to a nitrocellulose 
membrane (Whatman). The membrane was blocked with 5% 
skim milk in Tris-buffered saline (TBS) containing 0.2% tween-
20 at room temperature for 1 h and then incubated overnight with 
3B20 scFv-rabbit Fc (rFc) fusion protein (200 ng/mL), 3B20-
H1-13 scFv-rFc fusion protein (1 μg/mL), anti-ROS1 
antibodies (ab5512; 1:1000 dilution; Abcam), (3266; 1:1000 
dilution; Cell Signaling Technology) or anti-tubulin antibody 
(1:5000 dilution; Santa Cruz, Dallas, Texas, USA). The blots 
were washed five times with 0.2% tween-20 in TBS. HRP-
conjugated anti-rabbit IgG (Fc-specific) antibody (Abcam) and 
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anti-mouse IgG antibody (Pierce Chemical Co., Rockford, IL, 
USA) were used as secondary antibodies diluted 1:5000 in 
blocking buffer for 1 h at room temperature. The blots were 
visualized using the enhanced chemiluminescence system 
(Thermo Fisher Scientific), according to the manufacturer’s 
instructions. 
 
7. Immunoprecipitation and pull-down assay 
Lentiviral transduced HEK 293T cells which overexpress either 
ROS1 or GFP were lysed in cold lysis buffer [1% Triton X-100, 
150 mM NaCl, and 50 mM Tris. (pH8.0)] containing 1 mM PMSF 
(Merck), protease inhibitor cocktail (Roche), Phosphatase 
inhibition cocktail (Roche). Total lysates were incubated with 
3B20 scFv and 3B20-H1-13 scFv fused to rFc fusion protein 
(5 μg/mL) at 4℃ for overnight with rotation. The 20 μL of 
protein A agarose beads (Repligen) were washed three times 
with PBS and once with lysis buffer and added to lysates, 
followed by incubation at 4℃ for 4 h. After beads were washed 
three times with PBS, proteins bound beads were eluted by 
boiling in NuPAGE LDS Sample Buffer (Thermo Fisher Scientific) 
and subjected to immunoblots analysis, as described above. For 
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pull-down assay, eluted proteins were separated by SDS-PAGE 
gel and stained using Coomassie Blue R250 (Merck), according 
to the manufacturer’s instructions. 
 
8. Epitope mapping of anti-ROS1 scFv antibody, 3B20 
8-1. Preparation of alanine substituted proteins 
For epitope mapping of 3B20 scFv, alanine scanning mutagenesis 
assay was performed. Recombinant ROS1 (37-290 amino acid) 
protein was used as the template and amino acid residues from 
Gly42 through Ser54 of ROS1 were replaced with alanine by PCR 
experiment. Total of 13 residues were replaced with alanine one 
at a time; primer sequences were as follows: Forward: 5’- 
GGCCCAGGCGGCCTGTGTAACTAATCTG[GGC/CAG/CAG/CT
T/GAC/CTT/GGC/ACA/CCA/CAT/AAT/CTG/AGT]GAACCGTG
T-3’, Reverse: 5’- GGCCGGCCTGGCCTTCCTCTTGTTGAA 
CTGCTGA-3’ (each amino acid in the slash was replace with 
alanine). PCR was performed according to the initial denaturation 
at 94℃ for 5 min, 25 cycles of denaturation at 94℃ for 30 s, 
annealing at 55℃ for 30 s, extension at 72℃ for 1 min and final 
extension 72℃ for 10 min. PCR product was subjected to 1% 
agarose gel electrophoresis and purified using QIAquick Gel 
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Extraction Kit (Qiagen) according to the manufacturer ’ s 
instructions. Purified gene fused to modified human IgG1 Fc was 
sub-cloned into pCEP4 mammalian expression vector, as 
described above. 
 
8-2. ELISA using mutagenesis of the 3B20 scFv 
For alanine scanning mutagenesis of the 3B20 scFv, 96 well 
microtiter plates (Corning Costar Corp.) were coated with 100 
ng of the 3B20 scFv-CK fusion protein, BSA, or irrelevant scFv-
CK fusion protein overnight at 4℃ and blocked with 100 μL of 
3% BSA in PBS for 1 h. The plates were incubated with alanine 
substituted ROS1-hFc fusion proteins (each amino acid residue 
from Gly42 to Ser54 were replaced with alanine) and original (not 
replaced with alanine). After three times washing with 150 μL 
of 0.05% PBST, plates were incubated with HRP-conjugated 
Rabbit anti-Human IgG Fc antibody (1:5000 dilution; Thermo 
Fisher Scientific) for 1 h at 37℃. The plates were washed with 
150 μL of 0.05% PBST and binding of the alanine substituted 
ROS1 protein were determined by adding ABTS solution, as 




9. Site-directed HCDR3 mutagenesis libraries of the 3B20 
scFv 
To generate HCDR3 site-directed mutagenesis libraries, 3B20 
scFv was used as the template for library construction using 
degenerate codon NNK (N = A, T, G and C and K = G and T). 
First fragment was amplified using forward primer 5’-
CTGGCTGGTTTCGCTACCGTGGCC-3’ and reverse primer 5’
-TCTGGTGCAGTAGTAGGTGGC-3’ and second fragment was 
amplified using forward primer 5’-GCCACCTACTACTGCACCA 
GA[GGT/GGT/GGT/GGT/AAC/ATC/GAC/GCA]TGGGGCCAC-
3’ and reverse primer 5’-CGGGTATGCGCCATGGTGATGGT 
G)-3’ by PCR experiments, as described above (Each amino acid 
in the slash was replaced with NNK,). Subsequently, these PCR 
fragments were purified, followed by overlap extension PCR. 
One-hundred ng of PCR products were mixed in equal ratios to 
generate the overlap extension product as described above. The 
scFv genes, purified overlap extension PCR products, was ligated 
into the pComb3XSS phagemid vector followed by phage ELISA 





10. Enzyme-linked immunosorbent assay (ELISA) 
Ninety-six well microtiter plates (Corning Costar Corp.) were 
coated overnight at 4℃ with 100 ng of recombinant ROS1 (37-
290 amino acids)-CK fusion protein, the irrelevant protein-CK 
fusion molecule, the synthetic peptide (TNLGQQLDLGTPHNLSE 
PGGGC) or GRP75 (Enzo Life Sciences, Farmingdale, NY, USA) 
dissolved in coating buffer (0.1 M sodium bicarbonate, pH 8.6). 
Plates were blocked with 100 μL of 3% BSA in PBS for 1 h at 
37℃. Anti-ROS1 scFv antibodies, 3B20 scFv and 3B20-H1-13 
scFv fused to rFc were added to wells in a dose dependent 
manner in blocking buffer and incubated at 37℃ for 2 h. After 
three times washing with 0.05% PBST, plates were incubated 
with 50 μL of HRP-conjugated goat anti-rabbit IgG (Fc-
specific) antibody (1:5000 dilution in blocking buffer; Abcam, 
Cambridge science park, Cambridge, UK) for 1 h at 37℃. After 
three times washing, ABTS solution was added to each wells, and 
optical density was measured at 405 nm (Labsystems Multiskan 
Ascent microplate reader, Thermo Fisher Scientific).  
 
11. Mass spectrometry analysis 
Protein bands about 70 kDa and 260 kDa in the SDS-PAGE gel 
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were excised, and subjected to in-gel tryptic digestion as 
described previously. Excised protein bands were destained, 
reduced with 20 mM DTT, and then alkylated with 55 mM 
iodoacetamide. After dehydration with acetonitrile (ACN), the 
proteins were digested with 12.5 ng/μL modified trypsin 
(Promega, Madison, WI, USA) in 50 mM ammonium bicarbonate 
overnight at 37 °C. Peptides were extracted from the gel slices 
with 50% (v/v) ACN in 0.1% (v/v) formic acid (FA). The eluates 
were dried under a Centrivap concentrator (Labconco, Kansas 
City, MO, USA). Extracted peptide samples were suspended in 
0.1% formic acid in water, loaded onto an EASY-Spray C18 
column (75 µm×50 cm, 2 µm) and separated with a 2–35% 
gradient of 0.1% formic acid in acetonitrile for 65 min at a flow 
rate of 300 nL/min. MS spectra were recorded on a Q-Exactive 
hybrid quadrupole-Orbitrap mass spectrometer (Thermo Fisher 
Scientific) interfaced with a nano-ultra-HPLC system (Easy-
nLC1000; Thermo Fisher Scientific). Collected MS/MS raw files 
were converted to mzXML files using the Trans-Proteomic 
Pipeline (version 4.4) and analyzed using the Sequest (version 
27) algorithm in the SORCERER (Sage-N Research, Milpitas, CA, 
USA) platform. The search was performed using the IPI human 
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database (version 3.83, 186578 entries). Full tryptic specificity 
and up to two missed cleavage sites were allowed. Mass 
tolerances for precursor ions and fragment ions were set to 10 
ppm and 1 Da, respectively. Fixed modification for 
carbamidomethyl-cysteine and variable modifications for 
methionine oxidation were used. All proteins with a 
ProteinProphet probability of ≥ 99% with minimum three 
peptides and a PeptideProphet probability of ≥ 95% were 
identified using Scaffold (version 4.3.2; Proteome Software, 
Portland, OR, USA). 
 
12. Immunohistochemistry 
Representative paraffin blocks were cut into 4-μm-thick 
sections and examined for IHC using an automated 
immunostainer (Ventana BenchMark XT, Tuscan, AZ, USA). 
Heat-induced epitope retrieval with Ventana CC1 mild reagent 
was applied and endogenous peroxidase was blocked by 3% H2O2 
for 10 min. The slides were incubated with 3B20 scFv-rFc and 
3B20-H1-13-rFc (300 μg/mL stock; 1:100 dilution) fusion 





1. ELISA and immunoblot analysis with serum for 
confirmation of anti-ROS1 antibodies 
To generate an anti-ROS1 antibody, chicken serum ELISA was 
performed using ROS1 (37-290)-hFc fusion proteins, ROS1 
(37-290)-CK fusion proteins and ROS1 synthetic peptides 
(TNLGQQLDLGTPHNLSEPGGGC, amino acid 39-56 of ROS1) 
were conjugated with KLH (Figure 4). Following immunization of 
chickens with the peptide (39-56)-conjugated to KLH at the 
N-terminus, immunoblot assay was performed using chicken 
serum (Figure 5). 
 
2. Generation of the anti-ROS1 scFv libraries and screening 
for specific binding to the N-terminus of ROS1 
Using total RNAs isolated from the spleen, the bursa of Fabricius, 
and the bone marrow of immunized chicken, chicken scFv 
libraries with complexities of 8.7 x 109, 5.9 x 109, and 7.2 x 109 
was generated. The quality of the RNA, PCR products, and test 
ligation were assessed by electrophoresis with agarose gel and 
electroporation with test ligated samples (Figure 6). After five 
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rounds of bio-panning (Table 4), phage enzyme-linked 
immunosorbent assay (ELISA) was performed to isolate positive 
clones (Figure 7). Selected 3B20 scFv phage clones showed 
binding reactivity against both the recombinant N-terminus 
ROS1 (amino acid 37-290) CK fusion protein and the ROS1 
synthetic peptide (Figure 8A). Subsequently, the 3B20 scFv 
gene was sub-cloned into modified pCEP4 expression vectors 
containing the Fc region of rabbit IgG (scFv-rFc), which were 
transfected into HEK 293F cells using the PEI reagent. After five 
days, affinity chromatography was performed using protein A 
agarose beads in order to purify recombinant 3B20 scFv-rFc 
fusion proteins from the cultured supernatant. Binding reactivity 
of purified 3B20 scFv-rFc fusion proteins to recombinant ROS1 
proteins and peptides was evaluated by ELISA (Figure 8B). Pull-
down assays were performed using HEK 293T cells lysates 
transfected with lentiviral vectors encoding the human ROS1 
(full-length). These lysates were incubated with 3B20 scFv-
rFc fusion proteins and protein A agarose beads. After protein A 
agarose beads were washed, proteins bound to beads were 
eluted in the SDS-PAGE sample buffer. The eluted proteins 
were subjected to SDS-PAGE, and were identified using mouse 
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anti-ROS1 (69D6) mAbs (#3266; Cell signaling, Danvers, MA, 
USA). ROS1, which corresponded to a band with a molecular 
weight of 260 kDa, was clearly detected (Figure 9B). However, 
in the case of direct immunoblot assays using the 3B20 scFv, 
multiple bands including the recombinant ROS1 protein were 
detected from transfected cell lysates (Figure 9A). 
 
3. Identification of the putative antibody epitope from mass 
spectrometry and protein homology analysis 
To investigate the epitope of 3B20 scFv, pull-down assay was 
performed using 3B20 scFv-rFc fusion proteins from HEK 293T 
cells transfected with lentiviral vectors encoding the human 
ROS1 (full-length) and GFP (control) genes. Proteins bound to 
the 3B20 scFv protein were separated by SDS-PAGE. Following 
electrophoresis, the gel was stained with Coomassie Blue R250 
(Figure 10). Bands corresponding to 70 and 260 kDa were 
excised from the gel, and were analyzed by mass spectrometry 
(Figure 11). The top 10% of the spectral numbers were 
displayed in descending order, and as expected, the majority of 
ROS1 (Accession number: IPI0028965) proteins were detected 
at approximately 260 kDa (Figure 11). Due to non-specific 
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immunoblots bands at approximately 70 kDa, I investigated this 
region in more detail. Interestingly, 70 kDa heat shock proteins 
(Hsp70s) were also abundantly expressed in both ROS-
transfected and control gels. To determine the cause of 
unspecific binding to Hsp70s, the Hsp70s sequence was 
compared with that of the ROS1 protein using BLAST at the NCBI 
database. I found that both Hsp70s and ROS1 have the same 
amino acid sequence (Asp, Leu, Gly, and Tyr) in the exact same 
order. These sequences were identical to the D59 L60 G61 T62 
sequence of 75 kDa glucose regulated protein (GRP75), and can 
also be found in other members of Hsp70s. Therefore, I 
hypothesized that the epitope of the 3B20 scFv should be D46 L47 
G48 T49 in ROS1.  
 
4. Epitope mapping of the 3B20 scFv via alanine scanning 
mutagenesis assay 
To further confirm the epitope of the 3B20 scFv, alanine 
scanning mutagenesis assay was performed using phage form 
and recombinant ROS1 proteins (corresponding to 37-290 amino 
acids of ROS1). Each amino acid from Gly42 to Ser54 in the ROS1 
protein was substituted by alanine (Ala) (Figure 12). The 3B20 
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scFv-CK fusion protein (100 ng) or an irrelevant scFv-CK fusion 
protein was individually coated onto 96 well microtiter plates. 
After blocking the plate with BSA, alanine substituted mutant 
phage with different mutagenesis sites were added into each well. 
Binding reactivity of the alanine substituted ROS1 mutant phages 
to the 3B20 scFv was determined using HRP-conjugated M13 
antibodies (Figure 13A). Because pComb3XSS phagemid vector 
has a HA tag at the C terminus of the scFv, the anti-HA signal 
of phages was also determined for phage amplification. (Data not 
shown). The absorbance of phage amplification is set to 1, then 
the relative absorbance of ROS1 mutant binding is measured. The 
recombinant ROS1-hFc fusion protein (100 ng) substituted with 
alanine was also similarly coated. Following blocking, the 3B20 
scFv-CK fusion protein was added. The amount of bound 3B20 
scFv was determined using HRP-conjugated anti-CK antibodies 
and the ABTS solution (Figure 13B).  The amount of coated 
ROS1-hFc fusion protein was determined using HRP-
conjugated anti-hFc antibodies. (Data not shown) The 
absorbance of coated protein is set to 2, then the relative 
absorbance of the ELISA signal of 3B20 scFv binding is 
measured. (Data not shown). The three alanine substituted ROS1 
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mutants, Gly42Ala, Gln43Ala, and Gln44Ala showed slightly higher 
binding reactivity to the 3B20 scFv as compared with that of the 
recombinant ROS1 protein. On the contrary, Leu45Ala, Leu47Ala, 
and Gly48Ala mutants did not demonstrate binding reactivity to 
the 3B20 scFv (Figure 14A). The rest of the mutants showed 
similar or slightly lower binding reactivity to the 3B20 scFv. No 
background signal was detected in the blocking-buffer-only 
sample (Figure 14B) or the irrelevant scFv-CK fusion protein 
sample (Figure 14C). I concluded that Leu45, Leu47, and Gly48 of 
ROS1 play critical roles in binding specificity of the 3B20 scFv. 
 
5. Screening of modified 3B20 scFv with altered specificity 
from the HCDR3 site-directed mutagenesis libraries 
It was found that the 3B20 scFv demonstrate multi-reactivity 
via immunoblot and immunoprecipitation analyses. This was 
confirmed by mass spectroscopy, whereby 3B20 scFv was found 
to bind to Hsp70s. Reactivity of the 3B20 scFv to ROS1 and 
Hsp70 was assessed by ELISA (Figure 15). To eliminate non-
specific binding of the 3B20 scFv, I constructed HCDR3 site-
directed mutagenesis libraries through PCR. The 3B20 scFv 
consists of eight amino acids in the HCDR3, and each amino acid 
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was substituted with NNK degenerate codons (Figure 16). From 
the eight HCDR3 site-directed mutagenesis libraries 
constructed, 48 clones were selected, followed by amplification 
to phage. I then performed phage ELISA to evaluate their binding 
reactivity against both recombinant ROS1 and GRP75 (Figure 17). 
The anti-HA signal of phages was also determined for phage 
amplification, and it was confirmed that all phage signal was 
evenly amplified. (Data not shown). Relative absorbance after 
subtraction of the reduced blocking only was measured. 
Interestingly, some of the amino acid changes in HCDR3 had 
significant effects on antibody binding reactivity. Approximately 
60% of clones from libraries generated by NNK randomization at 
the 2nd, 3rd, or 4th amino acid position in the HCDR3 have lost 
their binding reactivity to recombinant ROS1, GRP75, or both 
ROS1 and GRP75. Approximately 30% of the clones from the 1st 
position randomized library lost their binding reactivity. On the 
other hand, 80-90% of the clones from 5th, 6th, 7th, and 8th 
position randomized libraries still maintained binding reactivity 
to both the recombinant ROS1 and GRP75. One candidate clone 
was isolated from the 1st position randomized library that 
exhibited binding reactivity to ROS1, but not to GRP75. Selected 
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candidate clones were sub-cloned into pCEP4-rFc vectors, and 
were transfected into HEK 293F cells. Following affinity 
purification using protein A agarose beads, the eluted protein was 
subjected to SDS-PAGE, and was stained by Coomassie Blue 
R250 (Figure 18). Reactivity of selected candidate clones to 
ROS1 and GRP75 was also determined by ELISA using the 
recombinant ROS1 protein (Figure 19) and the ROS1 peptide 
(Figure 20). Immunoblot was also performed to test binding of 
candidate clones to recombinant ROS1 proteins (Figure 21). 
Sequence of the final candidate clone was analyzed (Table 5), 
which confirmed substitution of glycine to lysine. This new 
candidate clone was named after its mutation, 3B20-H1-13.     
 
6. Specificity testing in the 2nd generation 3B20 scFv clone, 
3B20-H1-13  
To demonstrate the binding reactivity of 3B20-H1-13 scFv to 
ROS1, comparison experiments were performed with the 3B20 
scFv in parallel. The 3B20-H1-13 scFv screened from site-
directed mutagenesis NNK library showed improved specificity. 
Surprisingly, non-specific reactivity was no longer observed in 
the 3B20- H1-13 scFv (Figure 22A). Similar results were 
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obtained with immunoblots and pull-down assays (Figure 22B). 
Multiple bands resulting from non-specificity of the original scFv 
were removed when using the 3B20- H1-13 scFv. In addition, 
only single bands corresponding to the MW of the ROS1 protein 
was observed in pull-down assays, with the exception of the 
band corresponding to the 3B20-H1-13 scFv protein 
(approximately 55 kDa) bound to protein A agarose beads 
(Figure 22B).  
 
7. Expression of the full-length wild type ROS1 protein in 
human lung cancer 
To evaluate the applicability of the 3B20-H1-13 scFv in 
detection of the full-length wild type ROS1, immune-
histochemistry (IHC) was performed in human lung 
adenocarcinoma and non-neoplastic tissue samples (N = 100). 
HEK 293T cells transfected with lentiviral vectors encoding the 
full-length 3B20-H1-13 scFv was used as positive controls; 
strong membranous and intracellular ROS1 expression was found 
(Figure 23A). Alveolar macrophages served as internal positive 
control; benign bronchial epithelia and alveolar pneumocytes 
were negative for ROS1 expression (Figure 23B). 
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Adenocarcinoma cells showed variable degrees of ROS1 
expression, and strong positivity was found in approximately 10% 
of the cases. ROS1 was largely localized in intracellular 
membranes. However, intracellular ROS1 expression was also 
observed, especially in strong positive cases (Figure 23C-E). 
Some samples showed ROS1 expression in the membranes and 





































































Figure 2. General schematic of bio-panning which is an 












Figure 3. Construction of chicken scFv library 
Chicken Vλ and VH sequences were amplified for the 
construction of chicken scFv libraries. Each sense primer is 
combined with reverse primer to amplify gene segments from 
chicken cDNA. CSCVK and CSC-B have Sfi I restriction sites 
that are recognized by the extension primer in the overlap PCR. 
Primer CKJo-B and CSCVHo-FL have the sequence that 
corresponds to the long linker sequence that are used in the 
overlap extension PCR. The sense and reverse extension 
primers used in the second PCR recognize the sequence tails that 





Figure 4. ELISA with ROS1 peptide immunized chicken 
serum  
Three White Leghorn chickens were immunized with the ROS1 
N-terminus (39~56) peptide conjugated with KLH. Serum was 










Figure 5. Immunoblots with ROS1 peptide immunized 
chicken serum 
Immunoblots were performed to HEK 293T cells transfected 
with Lentiviral vector encoding human ROS1 cells using (A) 1st 
boosting serum and (B) 2nd boosting serum extracted from three 
immunized chicken’s blood. Arrow indicates the 260 kDa 









Figure 6. Construction of Chicken scFv libraries 
(A) Total RNAs was extracted from immunized chicken’s spleen, 
bursa of Fabricius and bone marrow. (B) First round of PCR was 
performed for VH and Vλ amplifications. (C) The number of 






Figure 7. Phage ELISA results of 3rd bio-panning 
A single colony from 3rd bio-panning out-put plates was 
cultured in SB media, and rescued phage was used for 










Figure 8. Reactivity of the selected anti-ROS1 scFv 
antibody to ROS1 
The binding affinity of the 3B20 scFv was measured by ELISA. 
The 3B20 scFv was prepared to (A) phage and (B) recombinant 














Figure 9. Reactivity of the selected anti-ROS1 scFv 
antibody to ROS1 in cell lysate 
(A) Immunoblot analysis of the 3B20 scFv. Cell lysates of HEK 
293T and U87MG cells transfected with lentiviral vector 
encoding ROS1, HEK 293T cells transfected GFP and wild type 
U87MG cells were subjected to SDS-PAGE. After transfer to 
nitrocellulose membranes and blocking, the membranes was 
probed with the 3B20 scFv-rFc fusion protein. (B) HEK 293T 
cells lentiviral transfected with ROS1 were lysed and incubated 
with the 3B20 scFv-rFc fusion protein and bound to protein A 
agarose beads. After washing steps, the protein bound to beads 






Figure 10. Pull-down assay of the 3B20 scFv 
HEK 293T cells transfected with lentiviral vector encoding ROS1 
were lysed and incubated with the 3B20 scFv-rFc fusion protein 
and bound to protein A agarose beads. After washing steps, the 
protein bound to beads was eluted and subjected to SDS-PAGE. 



























Figure 13. Reactivity of the alanine substituted recombinant 
ROS1 protein to the 3B20 scFv 
(A) The 3B20 scFv-rFc fusion protein and the control-CK 
protein were coated on 96 well microtiter plates. After blocking, 
ROS1 phages in which from 42 to 54 residue were replaced with 
alanine, respectively, were added. The amount of bound ROS1 
phages were determined using HRP-conjugated anti-M13 
antibody and ABTS solution. (B) Recombinant ROS1-hFc fusion 
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protein which is substituted alanine were coated on 96 well 
microtiter plates. After blocking, the 3B20 scFv-CK fusion 
protein was added, respectively. The amount of bound the anti-
ROS1 scFv antibody was determined using HRP-conjugated 
















Figure 14. Identification of the 3B20 scFv epitope by alanine 
scanning mutagenesis 
The wells of microtiter plates were coated with the 3B20 scFv-
CK fusion protein (A), BSA (B), or an irrelevant scFv-CK fusion 
protein (C). The plates were incubated with alanine substituted 
ROS1-hFc fusion proteins or wild type ROS1-hFc fusion protein 
in a dose dependent manner. The amounts of bound ROS1-hFc 
fusion proteins were determined using an HRP-conjugated anti-








Figure 15. Reactivity of the 3B20 scFv to ROS1 and Hsp70 
(GRP75) 
Recombinant ROS1 (amino acids 37-290)-CK fusion protein, 
GRP75 and control-CK protein were coated on 96 well microtiter 
plates. After blocking, the 3B20 scFv-rFc fusion protein was 
added. The amount of bound antibody was determined using 













Figure 17. Reactivity of site-directed HCDR3 libraries of the 
3B20 scFv to ROS1 and GRP75 
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Recombinant ROS1 (amino acids 37-290)-hFc fusion protein, 
GRP75 were coated on 96 well microtiter plates. After blocking, 
the 3B20 scFv-CK fusion protein was added, respectively. The 
amount of bound phage was determined using HRP-conjugated 
anti-M13 antibody and ABTS solution. Blank results were 
subtracted from the reading for all other wells, then ELISA 
graphs were described in ascending order based on the GRP75 

















Figure 18. Overexpression and purification of anti-ROS1 
scFv antibodies 
HEK 293F cells were transfected with selected anti-ROS1 scFv 
clones from site-directed HCDR3 libraries of the 3B20 scFv. 
After purification using protein A agarose beads, and purified 









Figure 19. Reactivity of selected anti-ROS1 scFv antibodies 
from site-directed HCDR3 libraries of the 3B20 scFv to 
ROS1 and GRP75 
Recombinant ROS1 (amino acids 37-290)-CK fusion protein, 
GRP75 and Control- CK fusion protein were coated on 96 well 
microtiter plates. After blocking, the 3B20 scFv-rFc fusion 
protein was added. The amount of bound antibody was 






Figure 20. Reactivity of selected anti-ROS1 scFv antibodies 
from site-directed HCDR3 libraries of the 3B20 scFv to 
ROS1 peptide 
Recombinant ROS1 (amino acids 37-290)-CK fusion protein, 
GRP75, Control- CK fusion protein and ROS1 N-terminus 
(39~56) peptide conjugated with BSA were coated on 96 well 
microtiter plates. After blocking, the 3B20 scFv-rFc fusion 
protein was added. The amount of bound antibody was 










Figure 21. Immunoblot analysis of selected anti-ROS1 scFv 
antibodies from site-directed HCDR3 libraries of the 3B20 
scFv 
Recombinant ROS1 (37-290)-CK fusion protein was loaded in 
non-reduced condition (NP) and reduced condition (R) in SDS-
PAGE and transferred onto nitrocellulose membranes. After 
blocking, the 3B20 scFv-rFc fusion protein and clones derived 
3B20 scFv were incubated with membranes. HRP-conjugated 
anti-rFc antibody and chemiluminescent substrate were used for 
visualization of the bands. The ab5512 was used by positive 





Figure 22. Specificity of 3B20 scFv and 3B20-H1-13 scFv 
(A) Cell lysates of HEK 293T cells transfected with lentiviral 
vector encoding ROS1 (lane R) or a control vector (lane C) were 
subjected to SDS–PAGE. After transfer to nitrocellulose 
membranes and blocking, the membraned were probed with 
antibodies, 3B20 scFv, 3B20–H1-13 scFv, or ROS1 (ab5515). 
Full-length ROS1 (arrow) was detected in lysates from cells 
transfected with ROS1. (B) HEK 293T cells transfected with 
GFP or ROS1 were lysed and incubated with 3B20 scFv and 
3B20–H1-13 scFv fused to rFc and bound to protein A agarose 
beads. After washing, the protein bound to beads was eluted and 
subjected to SDS–PAGE. The protein bands were visualized 




Figure 23. Results of immunohistochemistry with 3B20-
H1-13 scFv 
(A) HEK 293T cells transfected with lentiviral vector encoding 
human ROS1 (full-length) showed strong expression of ROS1 in 
the intracellular membrane and also in the cytoplasm (x400). (B) 
Non-neoplastic lung tissue was negative for ROS1 (x100). (C-
E) Expression of ROS1 was found in adenocarcinoma of the lung, 
in low levels (C x200), intermediate to high levels (D x200), and 
high levels (E x400; arrows show mitotic figures). (F) ROS1-
positive IHC was found in the intracellular membranes and 
cytoplasm of the tumor cells, with accentuation of membranous 




The proto-oncogene tyrosine kinase ROS1 has been considered 
to be a cancer-specific target molecule in both clinical and 
academic fields. So far, researchers have mainly focused on 
studying ROS1 rearrangements, ROS1 fusion proteins, and ROS1 
inhibitors. For example, the small molecule crizotinib (trade 
name Xalkori, Pfizer) is a representative ROS1 inhibitor that 
targets the C-terminus of the ROS1 fusion protein. However, 
studies on the full-length wild type ROS1 have not yet been fully 
established. Commercial anti-ROS1 antibodies have been 
developed. However, these antibodies mainly target the C-
terminal epitope of the ROS1 protein. ROS1 fusion proteins 
possess a 3′ region of ROS1 and a 5′ region from another partner. 
Hence, most commercially available antibodies target the C-
terminus of ROS1. These antibodies cannot identify, or be used 
for full-length ROS1 investigation. For example, the recently 
developed D4D6 is a good quality anti-ROS1 rabbit mAb that 
binds to the C-terminal epitope of ROS1. In addition, 
commercially available anti-ROS1 antibodies with N-terminal 
recognition site are very expensive and rare. Again, my 
preliminary test results demonstrated poor affinity and 
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specificity of these commercial antibodies as N-terminal ROS1 
target antibodies. Therefore, modified anti-ROS1 mAbs that 
exhibit enhanced specificity to the N-terminus of ROS1 have 
developed. 
The majority of ROS1-expressing cells have been reported to 
possess ROS1 fusion proteins, whereas cell expressing the full-
length ROS1 has not been found. Rimkunas et al. have previously 
reported that they were unable to identify cells expressing the 
full-length ROS1. My study has also attempted to isolate the 
full-length ROS1 in various cell lines. However, despite my 
many attempts, the full-length wild type ROS1 was not observed 
in any cell lines, except in lentivirus- infected cells. Recent 
studies suggested that ROS1 expression is higher in recurring 
tumors as compared with that in primary tumors. In addition, it 
has been reported that methylation inhibitors reduce ROS1 
promoter methylation, which leads to increased ROS1 expression. 
It was hypothesized that ROS1 expression is blocked under 




Based on my knowledge, this is the first study that showcases 
successful generation of the full-length ROS1 protein; the full-
length ROS1 protein was produced with developed expression 
system using the lentiviral vector. My study then developed the 
anti-ROS1 scFv antibody and 3B20, which demonstrated high 
reactivity and specificity for the target molecule as compared 
with commercial antibodies. Furthermore, my study was 
delineated epitope amino acid residues within the ROS1 proteins 
that play a critical role in the recognition of the 3B20 scFv. 
However, non-specific reactivity of the 3B20 scFv was detected 
in mass spectroscopy, immunoblots, and pull-down assays. The 
3B20 scFv binds to ROS1 with higher affinity as compared with 
that of commercial anti-ROS1 antibodies (ab5512). However, 
when using the 3B20 scFv, multiple specific bands were detected 
in immunoblot and pull-down assays. These multiple specific 
bands appeared at 70 kDa, which mass spectrometry revealed to 
be Hsp70s. Protein homology analysis indicated that the Hsp70s 
family shares the same binding sequence as ROS1. Hence, in this 
study was further investigated and verified that a member of the 
Hsp70s family, GRP75, can also bind to 3B20 scFv. GRP75 was 
commercially purchased, and binding reactivity of GRP75 was 
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measured using ELISA. As expected, GRP75 was able to bind to 
the 3B20 scFv. Therefore, elimination of non-specific binding is 
necessary to obtain high quality 3B20 scFv. 
Subsequently, my study tried to improve specificity of the 3B20 
scFv without losing its affinity for ROS1. The heavy chain 
complementarity-determining region 3 (HCDR3) is known to be 
the most important region for antibody-antigen interactions, and 
is associated with poly-reactivity. Thus, substitution within the 
HCDR3 region was carried out to alter its specificity. It is 
possible that substituted amino acids may not affect antibody-
antigen interactions. Indeed, studying individual HCDR3 site-
directed mutagenesis libraries will help us understand what 
residues are responsible for antibody-antigen interactions. This 
will be valuable for determining which residue is the best option 
for substitution, or which amino acid in HCDR3 is critical for 
antigen-antibody interactions. 
In summary, an anti-ROS1 N-terminal binding scFv antibody 
was successfully developed, and an individual NNK library of 
each amino acid position in the HCDR3 region have constructed 
to improve specificity of the clone. Although, a cell line that 
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expressed the full-length wild type ROS1 was not found, cells 
that expressed the full-length ROS1 protein using lentiviral 
vectors were generated. In this study, single amino acid changes 
in HCDR3 induced antibody binding specificity were 
demonstrated. Finally, an anti-ROS1 scFv antibody was 
developed and modified to show its potential for investigating the 
full-length ROS1. My opinion is that further studies on ROS1 
using this clone would reveal uncovered biological functions of 
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ROS1은 타이로신 카이네이즈 수용체로, 유전자는 염색체 6 번에 위치
하며 세포 내부의 타이로신 카이네이즈 도메인, 트랜스 멤브레인 그
리고 세포 외부 도메인으로 구성이 되는 약 265 kDa 정도의 크기의 단
백질이다. ROS 단백질은 염색체내의 빈번한 유전자 재배열 때문에 3’ 
의 ROS1 과 5’의 파트너 단백질의 재조합 형태로 발현된다. 이러한 재
조합 ROS1 단백질들을 이용한 연구는 꾸준히 수행되어 왔지만, 야생
형 ROS1 에 대해서는 현재까지 보고된 바가 많이 없다. 더구나 ROS1 
수용체는 알려진 라이간드가 없어 전체 길이의 야생형 ROS1 과 관련
된 특징 및 기능에 대한 연구도 부족하다. 현재, 전체 길이의 야생형 
ROS1 의 발현은 후성 유전학에 의해 조절이 된다는 가능성만이 제기
되고 있는 실정이며, 그렇기 때문에 야생형 ROS1 을 발현하는 세포주
를 개발하고, ROS1 의 N 말단에 결합하는 양질의 항체를 개발하고자 
하는 필요성이 대두되었다. 이러한 전체 길이의 야생형 ROS1 의 검출
과 연구를 위하여는 ROS1 의 N 말단 영역에 특이적으로 결합하는 항
체가 필요하고, 본 연구를 통하여 마침내 N 말단에 특이적으로 항원
반응성을 지닌 3B20 단일 사슬 항체가 개발되었다. 그러나 개발된 항
체의 특성 분석을 수행하던 중, 항원 특이성의 시험법인 면역블롯 
(immunoblot) 과 면역침강반응(immune-precipitation) 분석에서 열 
충격단백질(Hsp)70 패밀리에 대한 교차 반응성이 있음이 확인되었다. 
또한 전체길이의 야생형 ROS1이 과발현된 세포주에 대한 면역침강반
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응(Immunoprecipitation)과 질량분석(Mass spectrometry)의 실험 결과 아
스파르트산, 류신, 글라이신, 그리고 트레오닌(DLGT)의 아미노산을 
ROS1 과 Hsp70 패밀리가 공유하고 있음이 추가로 확인되었다. 개발
된 3B20 단일 사슬 항체의 항원인식부분인 항원 결정 부위를 알아보
기 위한 실험으로는 알라닌 스캐닝 돌연변이 유발(Alanine scanning 
mutagenesis)법이 수행되었고, 항체의 에피톱이 이 DLGT 아미노산을 
포함하고 있음이 증명되었다. 이렇게 3B20 단일 사슬 항체의 특성을 
분석하던 중 밝혀진 항체의 교차 반응성은 3B20 단일 사슬 항체의 중
쇄 상보성 결정 영역 3 에 무작위 돌연변이를 도입하여 해결하고자 하
였다. 결과적으로, 포인트 돌연변이가 도입된 새로운 3B20-H1-13 단일 
사슬 항체는 특이적으로 ROS1 에는 결합하나, Hsp70 패밀리의 일종인 
GRP75 에는 결합하지 않는다는 것이 효소면역측정법(ELISA) 및 면역
블롯, 면역침강반응 실험을 통해 증명되었다. 최종적으로는 변형된 
3B20-H1-13 단일 사슬 항체를 이용하여 전체 길이의 야생형 ROS1 의 
발현 여부를 조사하고자 하였고, 면역 조직 화학적 분석 (IHC)에서 
ROS1 은 종양이 아닌 폐 조직에서는 발견되지 않고 폐 선암에서 특이
적으로 과발현되어 있음을 확인하였다. 본 연구는 야생형 ROS1 의 N 
말단에 결합하는 단일 사실 항체의 개발과 개발 후 생산 및 특이성 증
대에 대하여 서술되었다. 선별된 항 ROS1 항체인 3B20 단일 사슬 클
론은 Hsp70 패밀리에 교차 반응성을 지니고 있었지만 중쇄 상보성 결
정 영역 3 (HCDR 3)에 무작위 돌연변이 유발을 사용하여 항체의 반응 
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특이성이 개선되었다. 이러한 3B20 단일 사슬 항체의 특이성은 최종적
으로 ROS1 에 대한 결합 친화도를 유지하면서 교차 반응성은 감소되
도록 유도되었다. 본 연구에서 개발된 ROS1 의 N 말단에 특이적으로 
결합하는 항체를 이용하면 야생형 ROS1 에 대한 발현 및 기능 연구에 
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